logo
Plus   Neg
Share
Email

Vertex Pharma: NHS England To Expand Reimbursement Agreement To Include KAFTRIO

Vertex Pharmaceuticals Incorporated (VRTX) has expanded its reimbursement agreement with NHS England for the company's cystic fibrosis medicines to include KAFTRIO, in a combination regimen with KALYDECO 150 mg. The expanded agreement includes reimbursed access to Vertex's currently licensed medicines - KALYDECO, ORKAMBI and SYMKEVI, as well as the triple combination therapy if approved.

The European Medicines Agency's Committee, CHMP, recently adopted a positive opinion for KAFTRIO in a combination regimen with KALYDECO 150 mg to treat people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation or two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
DMM Vission is recalling five lots of Cleaner Hand Sanitizer due to potential presence of methanol (wood alcohol), the U.S. Food & Drug Administration said in a statement. The company is yet to receive any reports of adverse events involving the product. Facebook Inc. said it will ban ads that seek to delegitimize the Presidential election. The announcement is in line with the social media giant's decision to prohibit ads that make premature declarations of victory as it aims to protect the integrity of the upcoming U.S. 2020 elections. Rob Leathern, Director of Product Management, in a tweet said that these changes apply to ads across Facebook... While reporting financial results for the first quarter of fiscal 2021 on Thursday, Conagra Brands, Inc. (CAG) provided only its adjusted earnings and organic net sales growth guidance for the second quarter of fiscal 2021. The company is still not initiating annual outlook, as is usual, as the impact...
Follow RTT